- $717.32m
- $569.96m
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec
Candel Therapeutics Q4 operating loss misses analyst expectations
Brief: Candel Therapeutics Q4 Net Income USD -29.496 Million
Brief: Candel Therapeutics Files For Offering Of 18.3 Mln Shares Of Common Stock
U.S. STOCKS ON THE MOVE-Homebuilders, solar stocks, Alphabet
U.S. STOCKS ON THE MOVE-Comfort Systems, Funko, Paymentus
U.S. STOCKS ON THE MOVE-Deckers Outdoor, CDT Equity, Comfort Systems
U.S. STOCKS ON THE MOVE-Akamai, Grail, Candel Therapeutics
Candel Therapeutics drops after $100 mln equity offering
Brief: Candel Therapeutics Announces Pricing Of Public Offering Of 18,348,624 Shares At $5.45 Each
Brief: Candel Therapeutics Announces Proposed $100 Million Public Offering
Brief: Candel Therapeutics Announces $100 Mln Royalty Funding Agreement With RTW
Candel Therapeutics falls after announcing $100 mln stock offering, royalty agreement
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Candel Therapeutics Q3 net loss widens to $11.3 mln
Brief: Candel Therapeutics Q3 Net Income USD -11.269 Million